PCOS Is Now PMOS: Because Most Women Never Had Ovarian Cysts

PCOS has a new official name: Polyendocrine Metabolic Ovarian Syndrome (PMOS).

The International PCOS Network, led by Prof. Helena Teede of Monash University, published a global consensus in The Lancet (2026) proposing the rename. The effort involved 56 patient and professional organizations worldwide. ASRM endorsed the change on May 27, 2026. The Society for Endocrinology confirmed the new name is to be fully implemented in the 2028 International Guideline update. The Endocrine Society and RANZCOG have also endorsed the change.

This is not a cutover. Both terms coexist during an approximately three-year transition period. Many clinicians will continue using PCOS until the 2028 guideline takes full effect. The diagnostic criteria, including the Rotterdam 2003 framework, are not overturned by the rename. The underlying condition is the same. The label is more accurate.

Why the Old Name Was Wrong

Most women diagnosed with PCOS do not have true ovarian cysts. A companion analysis included in the consensus found no increase in abnormal ovarian cysts compared to controls. The "polycystic" in PCOS is a misnomer. Those are follicles, not cysts. The ovaries are not the source of the disease. They are downstream of it.

The condition affects roughly 1 in 10 reproductive-age women, making it one of the most common endocrine disorders of reproductive age. Its documented effects reach far beyond the ovaries: insulin resistance, elevated androgens, cardiometabolic risk, elevated risk of type 2 diabetes, dermatologic manifestations such as acne and hirsutism, psychological burden including depression and anxiety, and disordered ovulation. Naming it after the ovaries, and after cysts that most patients do not have, has sent both patients and clinicians in the wrong direction for decades.

"Polyendocrine Metabolic" is a more honest description of what is actually happening. Multiple endocrine axes are dysregulated. Insulin resistance is central, not peripheral. The metabolic dimension carries real cardiovascular stakes that extend across a woman's lifetime, not just her reproductive years.

What This Means for How the Condition Gets Treated

A name shapes a treatment approach. If clinicians believe this is a disease of the ovaries, they treat the ovaries. If clinicians understand this is a multisystem endocrine and metabolic disorder, they ask a different and better question: what is driving the dysregulation, and can it be corrected?

The PMOS rename is, at its core, a call to treat root causes. Insulin resistance is not a side effect of PCOS. For many patients, it is the engine. Elevated androgens, disrupted ovulation, and anovulatory cycles are outputs. Address the metabolic drivers, and the ovulatory function often follows.

This is not a new idea in restorative reproductive medicine. RRM approaches this condition as a metabolic and endocrine problem from the first appointment. The goal is to evaluate what is actually dysregulated, restore ovulatory function, and address the systemic dimensions of the disease rather than suppress the cycle and call it managed. Hormonal suppression does not resolve insulin resistance. It does not restore ovulation. It does not reduce long-term cardiometabolic risk. It removes the signal. The underlying condition continues.

Couples dealing with PCOS-related infertility deserve to understand this distinction. Irregular ovulation is not simply a cycle inconvenience. It is a clinical finding pointing toward a measurable, addressable cause. Both partners are evaluated from the outset, because reproductive dysfunction is never solely one partner's problem. A cause-based workup looks at the full picture.

The Name Change Did Not Create This Framing. It Confirmed It.

The International PCOS Network described this as the largest initiative to rename a medical condition. That scale reflects how entrenched the wrong framing has been. Patients have spent years explaining to providers that their condition involves more than their ovaries. Many were told their insulin levels were normal enough, their metabolic risk was theoretical, their ovulatory irregularity was a fertility problem to address later.

The new name removes the basis for that dismissal. PMOS names the endocrine and metabolic reality of the condition explicitly. That matters for how providers screen, how patients understand their own bodies, and how the research community prioritizes its funding.

For anyone living with this diagnosis, nothing changes today. Your diagnosis is valid. Your records are valid. But pay attention to what just happened. A global panel of experts looked at the most common hormonal condition in women and concluded the name had been pointing at the wrong organ the entire time.

That is not a footnote. It is an admission. The "cyst" was never the disease. The metabolism was. And a name built on the wrong target tends to produce care built on the wrong target: decades of quieting the cycle instead of investigating what broke it.

Renaming the condition was the easy part. The harder question is whether the treatment model catches up. Does the next appointment start with insulin, androgens, and ovulation, or with one more prescription to mute the symptom? Restorative medicine never needed the new name to treat the metabolism. The rest of the field just made it official.

You do not have to wait until 2028 to be worked up like someone with a metabolic disease, because that is what PMOS has been the entire time. Read our full guide to the condition, now PMOS, and how restorative medicine treats it at the root.